Infectious Disease Alert – October 1, 2024
October 1, 2024
View Issues
-
The Rise of Oropouche Virus
Oropouche virus is an arthropod-borne virus that has been primarily endemic to the Amazon region. The incidence of Oropouche virus disease has significantly increased over the past few years, and recent outbreaks have been reported in areas without previous endemic transmission and have led to fatalities and vertical transmission resulting in adverse pregnancy outcomes.
-
Metformin Reduces SARS-CoV-2 Viral Load in Outpatients with COVID-19
A randomized, placebo-controlled clinical trial of outpatients with COVID-19 found that metformin reduced SARS-CoV-2 viral load 3.6-fold compared to placebo, while ivermectin and fluvoxamine showed no benefit.
-
Viruses, Newborns, and Liver Failure
Neonatal liver failure due to herpesvirus infection is rare but can be severe. Herpes simplex virus 1 (HSV-1) is a more likely cause than HSV-2. Only about two-thirds of affected patients survive, despite recommended treatment with parenteral acyclovir.
-
Twice-Yearly Subcutaneous Lenacapavir Injection Prevents HIV Infection
Subcutaneous injection of lenacapavir every 26 weeks had 100% efficacy in preventing human immunodeficiency virus (HIV) infection in a high-risk population.
-
Does Semaglutide Protect Against Adverse Effects from COVID-19?
Semaglutide recipients who developed COVID-19 had significant protection against the occurrence of adverse outcomes, including death.
-
Infectious Disease Updates
Managing Neurosyphilis; Combatting the Resurgence of Syphilis